Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
80%(4 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed583%
withdrawn117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

NCT03512249
completedphase_1

A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB

NCT02375698
completedphase_1

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

NCT02503839
completedphase_1

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

NCT02378207
completedphase_1

Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis

NCT01967134
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03512249Phase 2

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Completed
NCT02375698Phase 1

A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB

Completed
NCT02503839Phase 1

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

Completed
NCT02378207Phase 1

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

Completed
NCT01967134Phase 1

Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis

Completed
NCT03265977Phase 2

A Phase II Study of H56:IC31 in Healthy Adolescents

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6